Related Experiment Video
Updated: May 8, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Renal sympathetic denervation as antihypertensive therapy--a reappraisal of first results
Roland Veelken1, Johannes F E Mann
1Medizinische Klinik 4 (Nephrologie und Hypertensiologie), Friedrich Alexander Universitaet Erlangen-Nuernberg, Erlangen-Nuremberg, Germany.
Abstract:
Renal sympathetic denervation (RSD) has previously been discussed in this journal. Since then, it has become a common procedure in many countries to use RSD to treat patients with putatively resistant hypertension. In Germany alone, RSD is now routinely used to treat resistant hypertension at the expense of the health-care system. The Germans have established a national registry to systematically and continuously follow up hypertensive patients who have undergone RSD. However, there are concerns because the registry is voluntary and physicians practicing the procedure may not have the accrual of new knowledge regarding the utility of RSD as their primary professional aim. Since the previous editorial on renal denervation, new results have been published. Therefore, it is appropriate to re-evaluate RSD.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Vasodilators
Hypertension IV: Drug Therapy and Lifestyle Modifications
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Antihypertensive Drugs: Direct Renin Inhibitors
Antihypertensive Drugs: Action of β1 Blockers
